Safety and Efficacy of Intranasal Spray SARS-CoV-2 Vaccine dNS1-RBD
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
The Lancet Respiratory Medicine
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Safety and efficacy of the intranasal spray SARS-CoV-2 vaccine dNS1-RBD: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial
Lancet Respir Med 2023 Nov 15;[EPub Ahead of Print], F Zhu, S Huang, X Liu, Q Chen, C Zhuang, H Zhao, J Han, AM Jaen, TH Do, JG Peter, AG Dorado, LS Tirador, GMA Zabat, REM Villalobos, GP Gueco, LLG Botha, SP Iglesias Pertuz, J Tan, K Zhu, J Quan, H Lin, Y Huang, J Jia, X Chu, J Chen, Y Chen, T Zhang, Y Su, C Li, X Ye, T Wu, J Zhang, N XiaFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.